|
|
|
|
|
|
|
|
abstract
Purpose of review: The aim of this article was to review the
recent literature on potential therapeutic strategies for overcoming
resistance to antivascular endothelial growth factor drugs in ovarian
cancer.
Recent findings: Although clinical benefits of
antivascular endothelial growth factor therapy were observed in ovarian
cancer treatment trials, this use yielded only modest improvement in
progression-free survival and, with the exception of cediranib, no
effect on overall survival. Adaptive resistance and escape from
antiangiogenesis therapy is likely a multifactorial process, including
induction of hypoxia, vascular modulators, and immune response. New
drugs targeting the tumor vasculature or other components of the
surrounding microenvironment have shown promising results.
Summary: When to start and end antiangiogenesis therapy
and the choice of optimal treatment combinations remain controversial.
Further evaluation of personalized novel angiogenesis-based therapy is
warranted. Defining the critical interaction of these agents and
pathways and the appropriate predictive markers will become an
increasingly important objective for effective treatment.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.